Abstract: The present invention relates to novel amides and a process for preparing these amides.

Abstract: The present invention relates to acid addition salts of 4-[(4-methyl-1-piperazinyl)methyl]-N-(4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide, which are selected from the group consisting of a tartrate salt, such as a (D)(?) tartrate salt or a (L)(+) tartrate salt, a hydrochloride salt, a citrate salt, a malate salt, a fumarate salt, a succinate salt, a benzoate salt, a benzenesulfonate salt, a pamoate salt, a formate salt, a malonate salt, a 1,5-naphthalenedisulfonate salt, a salicylate salt, a cyclohexanesulfamate salt, a lactate salt, a mandelate salt, aq glutarate salt, an adipate salt, a squarate salt, a vanillate salt, an oxaloacetate salt, an ascorbate salt and a sulfate salt.

Abstract: A buried thin film resistor having end caps defined by a dielectric mask is disclosed. A thin film resistor is formed on an integrated circuit substrate. A resistor protect layer is formed over the thin film resistor. First and second portions of a first dielectric material are formed over the resistor protect layer over the first and second ends of the thin film resistor. The resistor protect layer is then wet etched using the first and second portions of the first dielectric material as a hard mask. Then a second dielectric layer is deposited. A first via mask and etch process is used to etch vias down to the underlying portions of the resistor protect layer over the ends of the thin film resistor. A second via mask and etch process is used to etch substrate vias to an underlying conductor layer.

Abstract: The present invention relates to a conjugate that comprises a) at least one compound to be delivered into or across a biological carrier, b) a delivery-enhancing transporter comprising at least 4 ?-homolysine residues, especially between 4 and 25 ?-homolysine residues, c) optionally a linker between the components a) and b), and d) optionally a labelling unit; to the salts of such conjugates; to a pharmaceutical composition comprising said conjugate; to a method for delivery of a compound into or across a biological barrier, the method comprising contacting the barrier with said conjugate; and to a process for the preparation of certain conjugates.

Abstract: The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]benzamide of formula 1, which may be used for example for tumor therapy.

Abstract: A screwless terminal, especially a modular terminal (1), with a conductor bar (3) situated in a terminal housing (2) and with an insulation displacement contact element (4) electroconductively connected to the conductor bar (3). An electrical conductor (11) that is introduced via a housing lead-through can be contacted between the cutting edges (7, 8) of the insulation displacement contact element (4) whereby the cutting edges (7,8) face each other. The insulation displacement contact element (4) is moveably arranged on the conductor bar (3). Insulation displacement contacting of the fixedly position conductor (11) is carried out by a translation movement of the insulation displacement contact element (4) along the conductor bar (3).

Abstract: An anti bruxism device for stopping or at least diminishing bruxism comprises a splint adapted to be secured to a tooth of a user, and a biofeedback system mounted on the splint. The biofeedback system includes a detector for detecting bruxism, and a stimulation device for stimulating the user responsive to detection of bruxism by the detector. The stimulation produced by the stimulation device causes the user to stop bruxating. Bruxism is a function that could damage teeth and molars, and may affect the neuro-muscular system in a negative way, and could cause, for example, headaches.